Patients will receive SNS-101 once every three weeks. Credit: YAKOBCHUK VIACHESLAV via shutterstock.com.

The US Food and Drug Administration (FDA) has granted clearance for Sensei Biotherapeutics’ investigational new drug (IND) application for SNS-101 enabling the initiation of a Phase I/II clinical trial to treat solid tumours.

The efficacy of SNS-101 as both a monotherapy and along with Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be assessed in the study.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics properties of SNS-101.

Patients will be administered an intravenous infusion of SNS-101 once every three weeks.

Sensei Biotherapeutics president and CEO John Celebi said: “Receiving IND clearance to advance our first conditionally active antibody into a Phase 1/2 clinical trial represents an important milestone for Sensei.

“We believe that SNS-101 has the potential to make a significant impact in the field and to improve the lives of cancer patients worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are delighted to bring SNS-101 into the clinic and explore its potential as a transformative treatment option for patients with solid tumours.”

The first patient of the Phase I/II study is expected to be dosed in the middle of this year.

The study’s Phase I dose escalation part will be followed by an expansion Phase II in selected patients on determining a recommended dose for Phase II .

SNS-101, a conditionally active, human monoclonal IgG1 antibody, selectively blocks the VISTA checkpoint in the tumour microenvironment.